CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

10x Genomics Q3 2026 net loss narrows 29% to $19.43 million

By Public Technologies
  • 10x Genomics' third-quarter 2026 net loss narrowed 29% year-over-year to $19.4 million, while revenue rose to $150.7 million.
  • Gross margin climbed 8 percentage points to 75% due primarily to lower inventory write-downs and product mix changes.
  • Global commercial shipments of Atera began, and the new Sentira cloud analysis platform was introduced.
  • Full-year 2026 revenue guidance increased to $625 million–$635 million from $610 million–$630 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 10x Genomics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA90509) on November 05, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk